Galmed Pharmaceuticals Ltd.
EOCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595353
No open-market purchases or sales by Galmed Pharmaceuticals Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $85.9K in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Galmed Pharmaceuticals Ltd. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +3 vs. Q2 2022
- Shares held
- 2.59M
- +63.1K (+2.5%) vs. Q2 2022
- Total value
- $803.6K
- −$895.8K (−52.7%) vs. Q2 2022
- New holders
- 5
- 3 more added
- Sold out
- 2
- 7 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EOCN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 14 | $85.9K |
| Q1 2026 | 16 | $71.2K |
| Q4 2025 | 17 | $166.4K |
| Q3 2025 | 14 | $102.0K |
| Q2 2025 | 15 | $140.2K |
| Q1 2025 | 13 | $80.4K |
| Q4 2024 | 12 | $142.8K |
| Q3 2024 | 10 | $38.3K |
| Q2 2024 | 13 | $112.9K |
| Q1 2024 | 13 | $57.6K |
| Q4 2023 | 14 | $248.8K |
| Q3 2023 | 17 | $428.2K |
| Q2 2023 | 12 | $419.1K |
| Q1 2023 | 21 | $878.3K |
| Q4 2022 | 22 | $1.21M |
| Q3 2022 | 25 | $803.6K |
| Q2 2022 | 22 | $1.70M |
| Q1 2022 | 23 | $4.47M |
| Q4 2021 | 24 | $7.05M |
| Q3 2021 | 26 | $11.8M |
| Q2 2021 | 25 | $14.6M |
| Q1 2021 | 30 | $19.4M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Galmed Pharmaceuticals Ltd.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| PYA Waltman Capital, LLC | 1,000 | $0 | 0.00% | 00.0% | Unchanged |
| Bourgeon Capital Management LLC | 500 | $0 | 0.00% | 00.0% | Unchanged |
| TD Waterhouse Canada Inc. | 1,000 | $423 | 0.00% | 00.0% | Unchanged |
| Federation des caisses Desjardins du Quebec | 2,500 | $778 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 4,050 | $1.00K | 0.00% | −2,280−36.0% | Reduced |
| TSFG, LLC | 3,000 | $1.00K | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 1,785 | $1.00K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 10,001 | $3.00K | 0.00% | −102−1.0% | Reduced |
| Brave Asset Management Inc | 11,470 | $4.00K | 0.00% | 00.0% | Unchanged |
| Ground Swell Capital, LLC | 13,028 | $4.00K | 0.01% | +13,028 | New |
| Jane Street Group, LLC | 13,904 | $4.00K | 0.00% | +13,904 | New |
| BNP Paribas Arbitrage, SA | 14,290 | $4.45K | 0.00% | +14,290 | New |
| Citadel Advisors LLC | 18,628 | $6.00K | 0.00% | −40,997−68.8% | Reduced |
| Two Sigma Securities, LLC | 18,512 | $6.00K | 0.00% | +18,512 | New |
| Virtu Financial LLC | 22,548 | $7.00K | 0.00% | +22,548 | New |
| Geode Capital Management, LLC | 27,177 | $8.00K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 26,986 | $8.00K | 0.00% | +20,922+345.0% | Added |
| Cambridge Investment Research Advisors, Inc. | 35,115 | $11.0K | 0.00% | +8,000+29.5% | Added |
| Millennium Management LLC | 46,866 | $15.0K | 0.00% | −3,882−7.6% | Reduced |
| Renaissance Technologies LLC | 50,789 | $16.0K | 0.00% | +19,189+60.7% | Added |
| Raymond James Financial Services Advisors, Inc. | 58,310 | $18.0K | 0.00% | −6,000−9.3% | Reduced |
| Western Wealth Management, LLC | 59,074 | $19.0K | 0.00% | 00.0% | Unchanged |
| Raymond James & Associates | 155,940 | $49.0K | 0.00% | −1,500−1.0% | Reduced |
| Morgan Stanley | 189,620 | $59.0K | 0.00% | −6,079−3.1% | Reduced |
| BVF Inc | 1,799,694 | $558.0K | 0.02% | 00.0% | Unchanged |
| Citigroup Inc | 0 | $0 | 0.00% | −3,700−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −2,750−100.0% | Sold out |